The stock has spent the past few years in the shadow of a COVID-19 boost, but it's time investors see the light.
GlaxoSmithKline (GSK – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Graham Parry from ...
CNBC on MSN10d
Moderna stock plunges nearly 17% after company lowers 2025 sales forecast by $1 billionShares of Moderna closed nearly 17% lower Monday. Other vaccine stocks also fell, with Novavax and BioNTech both ending more than 7% lower. "As we head into 2025, there are a handful of ...
Moderna (NASDAQ: MRNA) was one of the hottest companies of early pandemic times, delivering a coronavirus vaccine to market ...
David Risinger, an analyst from Leerink Partners, reiterated the Buy rating on Vaxcyte (PCVX – Research Report). The associated price target ...
BioSolutions' strategic turnaround plan and cost-cutting efforts are paving the way for profitability in 2025. Explore more ...
According to a 2023 PwC report, the AI market in healthcare was valued at $11 billion and is expected to grow to $188 billion by 2030. On January 21st, Oracle Co-founder Larry Ellison said during a ...
Valneva (VALN) announced results for its Phase 2 clinical trial evaluating the safety and immunogenicity of two different ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback